Standard BioTools Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Standard BioTools Inc. (LAB) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $3.59 million as of 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2025-05-06
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.59M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.59M.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.84M.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.84M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-03-31 | $3.59M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.59M 10-K · filed 2025-03-11 |
| 2024-09-30 | $2.84M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $2.84M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $2.87M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.41M 10-K · filed 2024-03-01 |
| 2023-09-30 | $1.41M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.41M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.41M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.77M 10-K · filed 2023-03-14 |
| 2022-09-30 | $11.77M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $11.77M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $12.45M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $12.57M 10-K · filed 2022-03-08 |
| 2021-09-30 | $12.58M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $12.60M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $12.59M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $12.71M 10-K · filed 2021-02-25 |
| 2020-09-30 | $12.67M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $12.63M 10-Q · filed 2020-08-07 |
| 2019-12-31 | $12.12M 10-K · filed 2020-02-27 |
| 2018-12-31 | $12.25M 10-K · filed 2019-03-18 |
| 2017-12-31 | $12.33M 10-K · filed 2018-03-08 |
| 2016-12-31 | $12.39M 10-K · filed 2017-03-03 |
| 2015-12-31 | $12.39M 10-K · filed 2016-02-29 |
| 2014-12-31 | $11.75M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |